GleamWall
中文EN

BLRX BioLineRx Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498403 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-95.9%
TTM net income YoY13.0%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin80.5%
Operating margin-871.8%
Net margin-680.2%
FCF margin-686.4%
EBITDA margin-829.8%

Returns

ROE-50.7%
ROA-20.1%
ROIC (approx.)-90.4%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio1.95x
Interest coverage-8.22x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-302022Q2*2022-06-302021Q2*2021-06-302020Q2*2020-06-302019Q2*2019-06-302018Q2*2018-06-30
Income statement
Revenue$304,000$5.39M$0—————
Cost of revenue$72,000$897,000$0—————
Gross profit$232,000$4.50M$0—————
R&D expense$2.33M$2.23M$3.01M$5.39M$5.14M$4.64M$5.30M$4.48M
SG&A expense$209,000$1.63M$1.30M$1.05M$1.04M$744,000$949,000$883,000
Operating income-$2.30M-$5.77M-$9.91M-$7.60M-$6.51M-$5.57M-$6.48M-$5.73M
Interest expense$276,000$2.08M$1.34M$379,000$242,000$396,000$440,000$11,000
Net income-$3.94M$484,000-$18.55M-$7.44M-$6.84M-$6.77M-$5.49M-$4.79M
EPS (basic)0.000.00-0.02-0.01-0.01-0.03-0.04-0.05
EPS (diluted)0.000.00-0.02-0.01-0.01-0.03-0.04-0.05
Weighted avg. shares (diluted)—1.20B922.96M—————
Balance sheet
Cash & equivalents$7.19M$9.62M$10.10M$14.00M$17.48M$5.52M$4.97M$5.79M
Receivables$78,000$3.18M——————
Inventory$2.85M$3.63M——————
Current assets$31.86M$49.11M$34.69M$44.10M$67.07M$28.17M$36.21M$42.80M
PP&E, netmay include right-of-use assets (IFRS)$197,000$344,000$648,000$810,000$1.14M$1.58M$2.05M$2.32M
Intangibles$10.41M$13.69M$22.01M$21.70M$21.71M$21.75M$21.93M$7.04M
Total assets$43.27M$64.60M$58.94M$67.84M$91.33M$52.99M$61.96M$52.21M
Current liabilities$15.48M$30.52M$12.45M$9.63M$9.92M$11.72M$8.56M$5.34M
Short-term debt$4.48M$10.66M$3.08M$1.01M$3.35M$2.87M$2.40M$93,000
Total liabilities$23.20M$50.62M$37.88M$11.27M$17.44M$23.76M$20.18M$6.03M
Shareholders' equity$20.07M$13.89M$21.05M$56.57M$73.89M$29.23M$41.78M$46.19M
Cash flow statement
Operating cash flow————————

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.